Application of PBPK to Personalized Dosing | Dr. Brahim Achour

Application of PBPK to Personalized Dosing | Dr. Brahim Achour

  • Register
    • Non-member - $49
    • Member - Free!
    • Student - Free!
    • Premier - Free!

Tailoring drug dosage regimens according to the patient’s characteristics and specific needs, or so-called personalized dosing, has recently been reinvigorated by the availability of novel technologies for characterizing patients and wider acceptance of simulated drug trials. The concept is most useful for dosing drugs with a narrow therapeutic index and for patients from special populations or those prone to polypharmacy. In these cases, refined dosing is essential in order to improve therapeutic response and lower the risk of toxicity. Recent advances in model-informed precision dosing are therefore expected to facilitate efforts towards wider implementation of individualized dosing in various clinical settings.


This webinar focuses on the practical application of modelling and simulation in the area of precision dosing. The course covers the development of virtual populations and the use of the Simcyp Simulator as a platform to build virtual twin avatars based on data generated using novel methods, such as liquid biopsy, whole genome sequencing and multi-‘omics’. Integration of liquid biopsy output with virtual twin models has the potential to significantly reduce uncertainty related to variability in predictions of drug exposure and allow the design of refined dosage regimens. The applications of this approach include effective clinical trial design in the drug development sphere and replacing the current ‘trial-and-error’ approach to dosing in clinical practice with model-informed decision making.

Brahim Achour

Application of PBPK to Personalized Dosing

Brahim Achour completed a PhD program in pharmacology and proteomics at the Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, in 2013, and is currently a research fellow at the same centre, overseeing research in the areas of liquid biopsy, precision dosing and proteomics. Dr Achour has co-authored more than 30 articles (H-factor=16), including a patent as co-inventor of a novel liquid biopsy test. Brahim has extensive experience in multi-'omics' with specific expertise in quantitative proteomics and transcriptomics as applied to pharmacologically-relevant pathways involved in drug metabolism and transport. Along with experimental work, Brahim has teaching and consultancy responsibilities for external and affiliated companies and institutions in relation to the use of systems data in PBPK and liquid biopsy applications.

Key:

Complete
Failed
Available
Locked
Application of PBPK to Personalized Dosing
Recorded 12/03/2020
Recorded 12/03/2020 Tailoring drug dosage regimens according to the patient’s characteristics and specific needs, or so-called personalized dosing, has recently been reinvigorated by the availability of novel technologies for characterizing patients and wider acceptance of simulated drug trials. The concept is most useful for dosing drugs with a narrow therapeutic index and for patients from special populations or those prone to polypharmacy. In these cases, refined dosing is essential in order to improve therapeutic response and lower the risk of toxicity. Recent advances in model-informed precision dosing are therefore expected to facilitate efforts towards wider implementation of individualized dosing in various clinical settings. This webinar focuses on the practical application of modelling and simulation in the area of precision dosing. The course covers the development of virtual populations and the use of the Simcyp Simulator as a platform to build virtual twin avatars based on data generated using novel methods, such as liquid biopsy, whole genome sequencing and multi-‘omics’. Integration of liquid biopsy output with virtual twin models has the potential to significantly reduce uncertainty related to variability in predictions of drug exposure and allow the design of refined dosage regimens. The applications of this approach include effective clinical trial design in the drug development sphere and replacing the current ‘trial-and-error’ approach to dosing in clinical practice with model-informed decision making.
Webinar Survey
4 Questions
Certificate of Attendance
No credits available  |  Certificate available
No credits available  |  Certificate available